Rodvold Keith A, Gotfried Mark H, Cwik Michael, Korth-Bradley Joan M, Dukart Gary, Ellis-Grosse Evelyn J
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.
J Antimicrob Chemother. 2006 Dec;58(6):1221-9. doi: 10.1093/jac/dkl403. Epub 2006 Sep 29.
The purpose of this study was to determine the tissue and corresponding serum concentration of tigecycline at selected time points in gall bladder, bile, colon, bone, synovial fluid (SF), lung and CSF in subjects undergoing surgical or medical procedures.
One hundred and four adult subjects (aged 24-83 years; 64 women, 40 men) received a single intravenous (i.v.) dose of tigecycline (100 mg infused over 30 min). Subjects were randomly assigned to one of four collection times at 4, 8, 12 and 24 h after the start of the infusion. For CSF, samples were collected at approximately 1.5 and 24 h after the start of the infusion. All subjects had serum samples collected before the administration of tigecycline, at the end of the infusion and at the time corresponding to tissue or body fluid collection. Drug concentrations in serum, tissues and body fluids were determined by LC/MS/MS. The area under the mean concentration-time curve from 0 to 24 h (AUC(0-24)) was determined for the comparison of systemic exposure between tissue or body fluid to serum.
The mean serum concentrations of tigecycline were similar to those previously published. Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.
A single 100 mg dose of intravenous tigecycline produced considerably higher tissue/fluid concentrations in bile, gall bladder, colon and lung compared with simultaneous serum concentrations. On average, the systemic exposure of tigecycline in bone, SF and CSF ranged from 11% to 41% of serum concentrations. The results in bone are inconsistent with previous radiolabelled studies in animals and it is unclear if tight binding to bone (versus low bone uptake) or poor extraction of tigecycline for LC/MS/MS detection or both may have contributed to the differences we observed in humans.
本研究旨在确定接受外科手术或内科治疗的受试者在选定时间点胆囊、胆汁、结肠、骨骼、滑液(SF)、肺和脑脊液中替加环素的组织浓度及相应血清浓度。
104名成年受试者(年龄24 - 83岁;64名女性,40名男性)接受单次静脉注射(i.v.)替加环素(100 mg,30分钟内输注完毕)。受试者在输注开始后4、8、12和24小时这四个采集时间点中随机分配。对于脑脊液,在输注开始后约1.5小时和24小时采集样本。所有受试者在替加环素给药前、输注结束时以及与组织或体液采集时间对应的时间采集血清样本。通过液相色谱/串联质谱法(LC/MS/MS)测定血清、组织和体液中的药物浓度。测定0至24小时平均浓度 - 时间曲线下面积(AUC(0 - 24)),以比较组织或体液与血清之间的全身暴露情况。
替加环素的平均血清浓度与先前发表的结果相似。以组织或体液中AUC(0 - 24)与血清中AUC(0 - 24)的比值表示的组织穿透力,胆汁为537,胆囊为23,结肠为2.6,肺为2.0,骨骼为0.41,滑液为0.31,脑脊液为0.11。
单次静脉注射100 mg替加环素后,胆汁、胆囊、结肠和肺中的组织/液浓度相比同时期血清浓度显著更高。平均而言,替加环素在骨骼、滑液和脑脊液中的全身暴露量为血清浓度的11%至41%。骨骼中的结果与先前动物放射性标记研究不一致,尚不清楚是替加环素与骨骼紧密结合(相对于低骨摄取)、还是替加环素用于LC/MS/MS检测的提取效果不佳、亦或是两者共同作用导致了我们在人体中观察到的差异。